Cravath’s New York Office Moves to Two Manhattan West
On June 26, 2024, Cravath partner David J. Kappos delivered a keynote address at the 15th annual Anaqua Experience Conference, which was held from June 24‑27, 2024, in Boston, MA. During his keynote entitled “Unveiling the Future: Macro‑Level Trends Shaping Intellectual Property,” Dave discussed the macro‑level trends reshaping the intellectual property landscape as the world evolves in the digital age, including emerging technologies and global regulatory shifts.
Deals & Cases
June 24, 2024
On June 24, 2024, Illumina, Inc. (“Illumina”), a global leader in DNA sequencing and array-based technologies, announced the successful completion of the spin-off of GRAIL, a healthcare company whose mission is to detect cancer early. This follows Illumina’s previously announced plans to divest GRAIL, and GRAIL is now a public and independent company. The separation was achieved through the distribution of 85.5% of the outstanding shares of GRAIL to holders of Illumina common stock on June 24, 2024. In addition to retaining their shares of Illumina common stock, Illumina shareholders received one share of GRAIL common stock for every six shares of Illumina stock held as of close of business on the record date of June 13, 2024. Illumina retained 14.5% of the outstanding shares of GRAIL common stock. Cravath represented Illumina in connection with the transaction.
Deals & Cases
May 07, 2024
On May 7, 2024, Ashland Inc. (“Ashland”), a global additives and specialty ingredients company, announced that it has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners LLC. Cravath is representing Ashland in connection with the transaction.
Deals & Cases
March 22, 2024
On March 21, 2024, ECN Capital Corp. (“ECN Capital”), a leading provider of business services to North American based banks, credit unions, life insurance companies, pension funds and institutional investors, announced the sale of Red Oak Inventory Finance (“Red Oak”) to BharCap Partners, a private investment firm. The transaction closed on February 21, 2024. Cravath represented ECN Capital in connection with the transaction.
Deals & Cases
February 28, 2024
On February 28, 2024, Viatris Inc. (“Viatris”), a global healthcare company, and Idorsia Ltd (“Idorsia”) announced they have entered into agreements for a significant global research and development collaboration under which Viatris will receive exclusive global development and commercialization rights to two Phase 3 assets as well as the potential to add additional innovative assets in the future.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.